SANA
Sana Biotechnology, Inc.
Price Chart
Latest Quote
$3.15
+0.11 (+3.62%)
Current Price
| Previous Close | $3.04 |
| Open | $3.08 |
| Day High | $3.20 |
| Day Low | $3.02 |
| Volume | 4,705,674 |
Stock Information
| Shares Outstanding | 278.29M |
| Total Debt | $82.63M |
| Cash Equivalents | $101.14M |
| Net Income | $-241.99M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $876.62M |
| EPS (TTM) | $-0.92 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $858.11M |
| Income | $-241.99M |
| Book/sh | $0.44 |
| Cash/sh | $0.36 |
| Employees | 142 |
Financial Ratios
| Quick Ratio | 1.17 |
| Current Ratio | 1.29 |
| Debt/Eq | 69.30 |
Returns & Margins
| ROA | -27.48% |
| ROE | -147.41% |
Ownership
| Insider Ownership | 6.51% |
| Institutional Ownership | 82.84% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -5.85 |
| P/B | 7.13 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $8.57 |
Technical Indicators
| SMA20 | $2.98 |
| SMA50 | $3.21 |
| SMA200 | $3.83 |
| RSI | 44.90 |
| ATR | 0.2146 |
| Shares Float | 177.72M |
| Short Float | 25.16% |
| Short Ratio | 9.49 |
| Volatility | 2.16 |
| Rel Volume | 1.67 |
Performance History
| Week | +13.72% |
| Month | +2.94% |
| Quarter | -0.63% |
| 6 Months | -37.00% |
| YTD | -24.82% |
| Year | +12.10% |
| 3 Years | -50.93% |
| 5 Years | -86.63% |
| 10 Years | -91.03% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $3.15 | 6,743,900 |
| 2026-06-17 | $3.04 | 6,254,600 |
| 2026-06-16 | $2.83 | 2,006,700 |
| 2026-06-15 | $2.85 | 2,786,000 |
| 2026-06-12 | $2.68 | 2,252,500 |
| 2026-06-11 | $2.77 | 2,952,000 |
| 2026-06-10 | $2.82 | 2,679,700 |
| 2026-06-09 | $2.82 | 8,767,100 |
| 2026-06-08 | $2.69 | 3,344,200 |
| 2026-06-05 | $2.68 | 4,682,400 |
| 2026-06-04 | $2.96 | 4,219,900 |
| 2026-06-03 | $3.12 | 2,585,400 |
| 2026-06-02 | $3.24 | 3,216,700 |
| 2026-06-01 | $3.21 | 3,401,900 |
| 2026-05-29 | $3.30 | 5,008,600 |
| 2026-05-28 | $3.13 | 6,174,000 |
| 2026-05-27 | $3.06 | 3,540,100 |
| 2026-05-26 | $3.05 | 4,075,500 |
| 2026-05-22 | $3.07 | 4,182,200 |
| 2026-05-21 | $3.15 | 2,070,200 |
| 2026-05-20 | $3.11 | 2,944,200 |
| 2026-05-19 | $3.06 | 3,389,500 |
About Sana Biotechnology, Inc.
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company's product pipeline includes UP421, a HIP-modified allogeneic primary islet cell product, which is in phase 1 clinical trial to treat type 1 diabetes; SC451, a HIP-modified, stem cell derived pancreatic islet cell therapy, which is in preclinical trial for the treatment of type 1 diabetes; SG293 and SG299, a CD8-targeted fusosome for the treatment of B cell hematologic malignancies and B cell mediated autoimmune diseases. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company has a strategic collaboration with Mayo Clinic for the development of SC451, a hypoimmune-modified pancreatic islet cell therapy for type 1 diabetes. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.
đ° Latest News
âI worry deeply about bioterrorismâ: Is Europe sufficiently prepared for another pandemic?
Euronews âĸ 2026-06-15T04:48:57Z
Sana Biotech (SANA), Mayo Clinic Partner to Advance Cell Therapy for Type 1 Diabetes
Insider Monkey âĸ 2026-04-27T06:22:08Z
Assessing Sana Biotechnology (SANA) Valuation After Mayo Clinic Partnership And Equity Investment
Simply Wall St. âĸ 2026-04-23T14:07:52Z
Wedbush Lifts PT on Sana Biotechnology (SANA) to $7 From $6
Insider Monkey âĸ 2026-04-20T21:30:15Z
Kailera nets $625M in one of biotechâs biggest-ever IPOs
BioPharma Dive âĸ 2026-04-16T20:38:00Z
âSana Biotechnology Inc. (SANA) Hits New Milestone on Cell Therapy for Type 1 Diabetes
Insider Monkey âĸ 2026-04-14T09:50:34Z
Sarepta tests new Elevidys safeguards; Sana advances diabetes cell therapy
BioPharma Dive âĸ 2026-03-16T09:06:00Z
Sector Update: Health Care Stocks Mixed Late Afternoon
MT Newswires âĸ 2026-03-13T19:49:42ZSector Update: Health Care Stocks Advance Friday Afternoon
MT Newswires âĸ 2026-03-13T17:49:45ZSana: Q4 Earnings Snapshot
Associated Press Finance âĸ 2026-03-03T21:39:03Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $205,708,000 | $270,832,000 | $286,127,000 | $272,564,000 |
| Other Income Expense | $-42,306,000 | $-6,398,000 | $-7,066,000 | $-674,000 |
| Other Non Operating Income Expenses | $2,305,000 | $-4,507,000 | $-52,000 | $-674,000 |
| Net Non Operating Interest Income Expense | $3,848,000 | $10,471,000 | $9,938,000 | $3,762,000 |
| Operating Expense | $205,708,000 | $270,832,000 | $286,127,000 | $272,564,000 |
| General And Administrative Expense | $44,296,000 | $64,040,000 | $73,299,000 | $71,561,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-244,166,000 | $-266,759,000 | $-283,255,000 | $-269,476,000 |
| Net Interest Income | $3,848,000 | $10,471,000 | $9,938,000 | $3,762,000 |
| Interest Income | $3,848,000 | $10,471,000 | $9,938,000 | $3,762,000 |
| Normalized Income | $-199,555,000 | $-264,868,000 | $-276,241,000 | $-269,476,000 |
| Net Income From Continuing And Discontinued Operation | $-244,166,000 | $-266,759,000 | $-283,255,000 | $-269,476,000 |
| Total Operating Income As Reported | $-250,319,000 | $-272,723,000 | $-293,141,000 | $-272,564,000 |
| Net Income Common Stockholders | $-244,166,000 | $-266,759,000 | $-283,255,000 | $-269,476,000 |
| Net Income | $-244,166,000 | $-266,759,000 | $-283,255,000 | $-269,476,000 |
| Net Income Including Noncontrolling Interests | $-244,166,000 | $-266,759,000 | $-283,255,000 | $-269,476,000 |
| Net Income Continuous Operations | $-244,166,000 | $-266,759,000 | $-283,255,000 | $-269,476,000 |
| Pretax Income | $-244,166,000 | $-266,759,000 | $-283,255,000 | $-269,476,000 |
| Special Income Charges | $-44,611,000 | $-1,891,000 | $-7,014,000 | - |
| Interest Income Non Operating | $3,848,000 | $10,471,000 | $9,938,000 | $3,762,000 |
| Operating Income | $-205,708,000 | $-270,832,000 | $-286,127,000 | $-272,564,000 |
| Per Share | ||||
| Diluted EPS | $-0.96 | $-1.16 | $-1.46 | $-1.43 |
| Basic EPS | $-0.96 | $-1.16 | $-1.46 | $-1.43 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-148,347,000 | $-253,441,000 | $-261,570,000 | $-256,939,000 |
| Total Unusual Items | $-44,611,000 | $-1,891,000 | $-7,014,000 | - |
| Total Unusual Items Excluding Goodwill | $-44,611,000 | $-1,891,000 | $-7,014,000 | - |
| Reconciled Depreciation | $12,750,000 | $15,500,000 | $17,543,000 | $15,625,000 |
| EBITDA (Bullshit earnings) | $-192,958,000 | $-255,332,000 | $-268,584,000 | $-256,939,000 |
| EBIT | $-205,708,000 | $-270,832,000 | $-286,127,000 | $-272,564,000 |
| Diluted Average Shares | $253,234,000 | $230,891,000 | $194,541,000 | $188,344,000 |
| Basic Average Shares | $253,234,000 | $230,891,000 | $194,541,000 | $188,344,000 |
| Diluted NI Availto Com Stockholders | $-244,166,000 | $-266,759,000 | $-283,255,000 | $-269,476,000 |
| Impairment Of Capital Assets | $44,611,000 | $1,891,000 | $7,014,000 | - |
| Research And Development | $161,412,000 | $206,792,000 | $212,828,000 | $201,003,000 |
| Selling General And Administration | $44,296,000 | $64,040,000 | $73,299,000 | $71,561,000 |
| Other Gand A | $44,296,000 | $64,040,000 | $73,299,000 | $71,561,000 |
| Tax Provision | - | - | - | - |
Fetched: 2026-06-18
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-38,938,000 | $50,682,000 | $87,684,000 | $299,493,000 |
| Total Assets | $416,890,000 | $501,020,000 | $565,299,000 | $822,720,000 |
| Total Non Current Assets | $268,214,000 | $340,212,000 | $351,784,000 | $378,283,000 |
| Other Non Current Assets | $3,173,000 | $5,121,000 | $6,370,000 | $9,007,000 |
| Goodwill And Other Intangible Assets | $199,822,000 | $199,822,000 | $199,822,000 | $199,822,000 |
| Other Intangible Assets | $59,195,000 | $59,195,000 | $59,195,000 | $59,195,000 |
| Current Assets | $148,676,000 | $160,808,000 | $213,515,000 | $444,437,000 |
| Other Current Assets | $6,099,000 | $4,479,000 | $4,488,000 | $14,374,000 |
| Restricted Cash | $4,195,000 | $3,832,000 | $3,832,000 | $6,100,000 |
| Cash Cash Equivalents And Short Term Investments | $138,382,000 | $152,497,000 | $205,195,000 | $423,963,000 |
| Cash And Cash Equivalents | $71,870,000 | $127,566,000 | $133,517,000 | $176,765,000 |
| Investmentin Financial Assets | - | - | $0 | $10,051,000 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $78,862,000 | $94,197,000 | $104,096,000 | $108,253,000 |
| Long Term Debt And Capital Lease Obligation | $63,924,000 | $81,663,000 | $90,901,000 | $95,860,000 |
| Current Debt And Capital Lease Obligation | $14,938,000 | $12,534,000 | $13,195,000 | $12,393,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $256,006,000 | $250,516,000 | $277,793,000 | $323,405,000 |
| Total Non Current Liabilities Net Minority Interest | $177,280,000 | $205,083,000 | $213,306,000 | $211,901,000 |
| Other Non Current Liabilities | $113,356,000 | $123,420,000 | $122,405,000 | $116,041,000 |
| Current Liabilities | $78,726,000 | $45,433,000 | $64,487,000 | $111,504,000 |
| Other Current Liabilities | $40,200,000 | - | - | $55,345,000 |
| Payables And Accrued Expenses | $11,860,000 | $21,471,000 | $31,506,000 | $22,517,000 |
| Payables | $1,669,000 | $5,210,000 | $4,108,000 | $2,857,000 |
| Accounts Payable | $1,669,000 | $5,210,000 | $4,108,000 | $2,857,000 |
| Equity | ||||
| Common Stock Equity | $160,884,000 | $250,504,000 | $287,506,000 | $499,315,000 |
| Total Equity Gross Minority Interest | $160,884,000 | $250,504,000 | $287,506,000 | $499,315,000 |
| Stockholders Equity | $160,884,000 | $250,504,000 | $287,506,000 | $499,315,000 |
| Gains Losses Not Affecting Retained Earnings | $28,000 | $14,000 | $-60,000 | $-4,327,000 |
| Other Equity Adjustments | $28,000 | $14,000 | $-60,000 | $-4,327,000 |
| Retained Earnings | $-1,849,016,000 | $-1,604,850,000 | $-1,338,091,000 | $-1,054,836,000 |
| Other | ||||
| Ordinary Shares Number | $266,731,648 | $223,923,000 | $197,857,000 | $191,022,000 |
| Share Issued | $266,731,648 | $223,923,000 | $197,857,000 | $191,022,000 |
| Tangible Book Value | $-38,938,000 | $50,682,000 | $87,684,000 | $299,493,000 |
| Invested Capital | $160,884,000 | $250,504,000 | $287,506,000 | $499,315,000 |
| Working Capital | $69,950,000 | $115,375,000 | $149,028,000 | $332,933,000 |
| Capital Lease Obligations | $78,862,000 | $94,197,000 | $104,096,000 | $108,253,000 |
| Total Capitalization | $160,884,000 | $250,504,000 | $287,506,000 | $499,315,000 |
| Additional Paid In Capital | $2,009,845,000 | $1,855,318,000 | $1,625,637,000 | $1,558,459,000 |
| Capital Stock | $27,000 | $22,000 | $20,000 | $19,000 |
| Common Stock | $27,000 | $22,000 | $20,000 | $19,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $63,924,000 | $81,663,000 | $90,901,000 | $95,860,000 |
| Current Capital Lease Obligation | $14,938,000 | $12,534,000 | $13,195,000 | $12,393,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $11,728,000 | $11,428,000 | $19,786,000 | $21,249,000 |
| Current Accrued Expenses | $10,191,000 | $16,261,000 | $27,398,000 | $19,660,000 |
| Goodwill | $140,627,000 | $140,627,000 | $140,627,000 | $140,627,000 |
| Net PPE | $65,219,000 | $135,269,000 | $145,592,000 | $159,403,000 |
| Accumulated Depreciation | $-54,755,000 | $-54,166,000 | $-41,771,000 | $-33,977,000 |
| Gross PPE | $119,974,000 | $189,435,000 | $187,363,000 | $193,380,000 |
| Leases | $39,061,000 | $33,344,000 | $31,361,000 | $34,427,000 |
| Construction In Progress | $0 | $40,337,000 | $26,332,000 | $1,711,000 |
| Other Properties | $76,775,000 | $110,918,000 | $126,546,000 | $154,328,000 |
| Machinery Furniture Equipment | $4,138,000 | $4,836,000 | $3,124,000 | $2,914,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $66,512,000 | $24,931,000 | $71,678,000 | $247,198,000 |
| Investments And Advances | - | - | $0 | $10,051,000 |
| Available For Sale Securities | - | - | - | $10,051,000 |
Fetched: 2026-06-18
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-144,766,000 | $-256,583,000 | $-273,614,000 | $-310,926,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-143,828,000 | $-223,153,000 | $-253,582,000 | $-290,050,000 |
| Cash Flow From Continuing Operating Activities | $-143,828,000 | $-223,153,000 | $-253,582,000 | $-290,050,000 |
| Investing Activities | ||||
| Capital Expenditure | $-938,000 | $-33,430,000 | $-20,032,000 | $-20,876,000 |
| Investing Cash Flow | $-40,238,000 | $17,453,000 | $172,012,000 | $210,562,000 |
| Cash Flow From Continuing Investing Activities | $-40,238,000 | $17,453,000 | $172,012,000 | $210,562,000 |
| Net Other Investing Changes | $1,432,000 | - | - | - |
| Financing Activities | ||||
| Financing Cash Flow | $128,733,000 | $199,749,000 | $31,646,000 | $4,913,000 |
| Cash Flow From Continuing Financing Activities | $128,733,000 | $199,749,000 | $31,646,000 | $4,913,000 |
| Issuance Of Capital Stock | - | $181,000,000 | $31,646,000 | $601,000 |
| Net Common Stock Issuance | - | $181,000,000 | $31,646,000 | $601,000 |
| Common Stock Issuance | - | $181,000,000 | $31,646,000 | $601,000 |
| Net Preferred Stock Issuance | - | - | - | $0 |
| Preferred Stock Issuance | - | - | - | $0 |
| Other | ||||
| Repayment Of Debt | $-347,000 | - | - | - |
| Issuance Of Debt | $126,404,000 | $188,744,000 | $27,020,000 | $0 |
| End Cash Position | $76,065,000 | $131,398,000 | $137,349,000 | $187,273,000 |
| Beginning Cash Position | $131,398,000 | $137,349,000 | $187,273,000 | $261,848,000 |
| Changes In Cash | $-55,333,000 | $-5,951,000 | $-49,924,000 | $-74,575,000 |
| Proceeds From Stock Option Exercised | $2,676,000 | $11,005,000 | $4,626,000 | $4,312,000 |
| Net Issuance Payments Of Debt | $126,057,000 | $188,744,000 | $27,020,000 | $0 |
| Net Long Term Debt Issuance | $126,057,000 | $188,744,000 | $27,020,000 | $0 |
| Long Term Debt Payments | $-347,000 | - | - | - |
| Long Term Debt Issuance | $126,404,000 | $188,744,000 | $27,020,000 | $0 |
| Net Investment Purchase And Sale | $-40,732,000 | $50,883,000 | $192,044,000 | $231,438,000 |
| Sale Of Investment | $46,561,000 | $276,947,000 | $349,788,000 | $310,126,000 |
| Purchase Of Investment | $-87,293,000 | $-226,064,000 | $-157,744,000 | $-78,688,000 |
| Net PPE Purchase And Sale | $-938,000 | $-33,430,000 | $-20,032,000 | $-20,876,000 |
| Purchase Of PPE | $-938,000 | $-33,430,000 | $-20,032,000 | $-20,876,000 |
| Change In Working Capital | $-10,114,000 | $-1,185,000 | $18,611,000 | $7,542,000 |
| Change In Other Working Capital | $-2,997,000 | $9,341,000 | $10,959,000 | $1,562,000 |
| Change In Payables And Accrued Expense | $-8,282,000 | $-7,013,000 | $-491,000 | $11,968,000 |
| Change In Accrued Expense | $-4,737,000 | $-8,390,000 | $-1,518,000 | $10,910,000 |
| Change In Payable | $-3,545,000 | $1,377,000 | $1,027,000 | $1,058,000 |
| Change In Account Payable | $-3,545,000 | $1,377,000 | $1,027,000 | $1,058,000 |
| Change In Prepaid Assets | $1,165,000 | $-3,513,000 | $8,143,000 | $-5,988,000 |
| Other Non Cash Items | $27,627,000 | $-10,278,000 | $-49,028,000 | $-82,078,000 |
| Stock Based Compensation | $25,464,000 | $37,678,000 | $35,533,000 | $38,337,000 |
| Asset Impairment Charge | $44,611,000 | $1,891,000 | $7,014,000 | - |
| Depreciation Amortization Depletion | $12,750,000 | $15,500,000 | $17,543,000 | $15,625,000 |
| Depreciation And Amortization | $12,750,000 | $15,500,000 | $17,543,000 | $15,625,000 |
| Depreciation | $12,750,000 | $15,500,000 | $17,543,000 | $15,625,000 |
| Net Income From Continuing Operations | $-244,166,000 | $-266,759,000 | $-283,255,000 | $-269,476,000 |
| Net Business Purchase And Sale | - | - | - | - |
| Purchase Of Business | - | - | - | - |
| Deferred Tax | - | - | - | - |
| Deferred Income Tax | - | - | - | - |
Fetched: 2026-06-18